Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLU-IGIV in Hospitalized Serious Influenza A
NCT03315104Phase 2Completed
- Sponsor
- Emergent BioSolutions
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- IgG Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of FLU-IGIV in Influenza A infection, sponsored by Emergent BioSolutions. Started Nov 2017; status: completed.
02
Drugs
FLU-IGIV
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NCT03315104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315104.